Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Combination trials by nature are highly complex and if I recall correctly Sierra didn’t finish the PD-L1 pre clinical so there’s a high possibility SRA737 is currently undergoing pre clinical in combination with X and if X is a new drug they will have to file for an IND at some point.
AZD1775 is a Wee1 inhibitor by AZ
We know that SO in their final trial design it was indicated
Sra737 plus either Parpi
SRA737 plus Wee1.
This from early 2022.
The other aspect here to take into consideration here is drug repurposing. In addition cost cutting.
It takes years and millions of pounds to bring a drug to phase1 trial.
Most of the drugs with their strengths and weaknesses are known.
It would be prudent to suggest that far more can be made in suitable drug in combo therapy, bu specialist organisations that result in a far more effective treatment as well as prolong the saleability of drugs in current commercialisation.
Then their comes the patent protection, and along with any new patent comes patent protection defeating the onset of generic drugs.
It gets complex.
Regards.
Salient points indeed SOG.
Certainly encouraging results even though just a pre clinical study.
“Importantly, in a transgenic mouse model of NEPC, both agents alone or in combination suppressed tumor growth, improved overall survival, and reduced the incidence of distant metastases, with SRA737 exhibiting remarkable single agent anticancer activity. Mechanistically, SRA737 synergized with AZD1775 by blocking AZD1775-induced feedback activation of CHK1 in prostate cancer cells, resulting in increased mitotic entry and accumulation of DNA damage. In summary, this preclinical study shows that CHK1 inhibitor SRA737 alone and its combination with AZD1775 offer potential effective treatments for CRPC and NEPC.”
I doubt that very much.
Ad l see it the problem arises that in, in combo therapy more than 1 inhibitor is used.
Unlikely therefore that a large pharma would take on.
However, on the upside a research pharma being small can establish a most satisfactory in combo therapy with different owners of individual inhibitors.
A plus B and C work well in investigational.
Then from this there will be a need to trial on clinical trial.
Multi compound in combo therapy owned by different companies.
There will need to be an agreement whether in licence format or a contract of some sorts, to establish milestone payments and the future predicted values of this in combo therapy.
Sra 737 is ok as licenced to private pharma.
I am of the firm opinion of this private pharma is aiming to develop a satisfactory in combo treatment leading to commercialisation.
In this instance there will exist agreements/ permissions of somesort to allow clinical trial to progress.
Now we get to the point of funding.
Where does the funding originate from?
Is it supplied by a financial investor or finance carried out paid for by the owners of such as the PD-1 or Wee1 inhibitor for example.
This may be the main reason why the private pharma identity is not disclosed.
Just my thoughts on this one.
Small pharma can generate pre clinical investigational data on more than 1 combo therapy. Most likely they will already have this info.
On good data results the owners of the other inhibitors can be contacted to establish an interest xnd if so how much are they willing to pay upfront and and financial renumeration in detail.
Regards
Interesting that this trial of SRA737 was conducted with and without AZ’s AZD-1775.
Could this indicate that AstraZeneca is the unnamed partner.???
SRA737 for prostate cancer
“SRA737 exhibiting remarkable single agent anticancer activity”
Apologies if already posted
https://www.researchgate.net/publication/377699214_Synthetic_lethal_combination_of_CHK1_and_WEE1_inhibition_for_treatment_of_castration-resistant_prostate_cancer